Description:Pimasertib, with the CAS number 1236699-92-5, is a small molecule inhibitor that primarily targets the mitogen-activated protein kinase (MAPK) pathway, specifically the MEK1 and MEK2 enzymes. It is classified as a selective MEK inhibitor and has been investigated for its potential therapeutic applications in various cancers, particularly those with mutations in the RAS or RAF genes. Pimasertib exhibits characteristics such as moderate solubility in organic solvents and a relatively low molecular weight, which facilitates its absorption and distribution in biological systems. The compound has been studied in clinical trials, often in combination with other anticancer agents, to enhance therapeutic efficacy and overcome resistance mechanisms. Its mechanism of action involves the inhibition of downstream signaling pathways that promote cell proliferation and survival, making it a candidate for targeted cancer therapy. As with many investigational drugs, the safety profile and pharmacokinetics of Pimasertib are critical areas of ongoing research to determine its clinical utility.
We use cookies to enhance your visit. We do not include advertising.
Please see our Cookies Policy for more details or adjust your preferences in "Settings".
This is the advanced settings system for our own and third-party cookies. Here you can modify parameters that will directly affect your browsing experience on this website. If you wish you may check the list of Cookie types.
Please note that disabling cookies can cause failures in the normal operation of the web.
![4-Pyridinecarboxamide, N-[(2S)-2,3-dihydroxypropyl]-3-[(2-fluoro-4-iodophenyl)amino]-](https://static.cymitquimica.com/products/IN/thumb/DA000KXC.jpg)
